Skip to content

Randomised controlled trial to evaluate tolerance of a new fibre-enriched sip feed in subjects in need of oral nutritional support.

Randomised controlled trial to evaluate tolerance of a new fibre-enriched sip feed in subjects in need of oral nutritional support.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26327
Enrollment
50
Registered
2009-11-17
Start date
2009-11-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Interventions

Intervention group: new fibre-enriched sip feed
Control group: standard fibre-enriched sip feed.

Sponsors

Danone Research – Centre for Specialised Nutrition
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects (male/female) ≥ 50 years of age at the start of the Baseline period; 2. Subject is prescribed oral nutritional support of  300 kcal/day of sip feed (subject can be current or new user); 3. In case of new users: MUST score 1 (medium risk of malnutrition), or 2 or more (high risk of malnutrition); 4. Subject is expected to require oral nutritional support for at least 4 weeks; 5. Subject has given written informed consent; 6. Subject is able to comply with the protocol (e.g. answer questions).

Exclusion criteria

Exclusion criteria: 1. Known inflammatory bowel diseases (e.g. Crohn’s disease); 2. Known lactose intolerance and not using lactase; 3. Known galactosemia; 4. Known cow’s milk allergy; 5. Known major hepatic dysfunction: symptomatic hepatic dysfunction or previous serum transaminase (ALAT, ASAT, or alkaline phosphatase) levels more than 5 times upper limit of normal; 6. Known major renal dysfunction: symptomatic renal dysfunction, previous serum creatinine level more than 1.8 times upper limit of normal, or requiring dialysis; 7. Subject with an ileostomy or colostomy; 8. Parenteral feeding; 9. Tube feeding; 10. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements; 11. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Design outcomes

Primary

MeasureTime frame
Tolerance, daily: 1. Stool frequency; 2. Incidence of liquid stools; 3. Incidence and intensity gastrointestinal symptoms.

Secondary

MeasureTime frame
1. Study product intake; 2. Product appreciation.

Contacts

Public ContactMarjolein Miltenburg, van

PO Box 7005

Marjolein.vanmiltenburg@danone.com+31 (0)317 467 800

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)